STAAR Surgical (NASDAQ:STAA) Director Buys $959,465.28 in Stock

STAAR Surgical Company (NASDAQ:STAA) Director Broadwood Partners, L.P. acquired 54,764 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was purchased at an average cost of $17.52 per share, for a total transaction of $959,465.28. Following the transaction, the director owned 15,508,393 shares in the company, valued at approximately $271,707,045.36. The trade was a 0.35% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Friday, March 13th, Broadwood Partners, L.P. bought 316,017 shares of STAAR Surgical stock. The shares were purchased at an average cost of $18.61 per share, with a total value of $5,881,076.37.
• On Thursday, March 12th, Broadwood Partners, L.P. bought 299,432 shares of STAAR Surgical stock. The stock was purchased at an average price of $18.12 per share, with a total value of $5,425,707.84.
• On Friday, January 9th, Broadwood Partners, L.P. purchased 27,485 shares of STAAR Surgical stock. The shares were acquired at an average cost of $22.05 per share, for a total transaction of $606,044.25.
• On Thursday, January 8th, Broadwood Partners, L.P. acquired 3,240 shares of STAAR Surgical stock. The shares were acquired at an average price of $21.94 per share, with a total value of $71,085.60.
• On Wednesday, January 7th, Broadwood Partners, L.P. acquired 66,467 shares of STAAR Surgical stock. The stock was acquired at an average cost of $22.00 per share, with a total value of $1,462,274.00.
• On Tuesday, January 6th, Broadwood Partners, L.P. bought 336,946 shares of STAAR Surgical stock. The shares were acquired at an average price of $21.62 per share, for a total transaction of $7,284,772.52.

STAAR Surgical Price Performance

Shares of NASDAQ:STAA opened at $18.84 on Monday. STAAR Surgical Company has a 1 year low of $14.69 and a 1 year high of $30.81. The firm has a market capitalization of $932.77 million, a P/E ratio of -11.56 and a beta of 1.04. The business’s 50-day moving average is $19.16 and its 200 day moving average is $23.66.

STAAR Surgical (NASDAQ:STAA) last posted its earnings results on Tuesday, March 3rd. The medical instruments supplier reported ($0.37) EPS for the quarter, missing the consensus estimate of $0.14 by ($0.51). The company had revenue of $57.80 million for the quarter, compared to analyst estimates of $75.54 million. STAAR Surgical had a negative return on equity of 10.03% and a negative net margin of 33.60%.The firm’s revenue for the quarter was up 18.0% compared to the same quarter last year. On average, analysts expect that STAAR Surgical Company will post -1.14 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd grew its stake in STAAR Surgical by 2,605.1% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 1,016 shares during the period. GAMMA Investing LLC increased its holdings in STAAR Surgical by 61.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,856 shares of the medical instruments supplier’s stock worth $50,000 after acquiring an additional 706 shares in the last quarter. PNC Financial Services Group Inc. raised its position in STAAR Surgical by 691.0% during the second quarter. PNC Financial Services Group Inc. now owns 3,607 shares of the medical instruments supplier’s stock worth $61,000 after acquiring an additional 3,151 shares during the period. Tower Research Capital LLC TRC lifted its holdings in STAAR Surgical by 375.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 4,673 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in STAAR Surgical by 9,928.9% during the third quarter. Russell Investments Group Ltd. now owns 4,513 shares of the medical instruments supplier’s stock valued at $121,000 after purchasing an additional 4,468 shares in the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Analyst Upgrades and Downgrades

STAA has been the subject of several recent research reports. Jefferies Financial Group cut their target price on shares of STAAR Surgical from $28.00 to $21.50 and set a “buy” rating for the company in a report on Wednesday, January 28th. BTIG Research restated a “neutral” rating on shares of STAAR Surgical in a research report on Tuesday, January 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a report on Tuesday, January 6th. Morgan Stanley started coverage on shares of STAAR Surgical in a research report on Friday, January 16th. They issued an “underweight” rating and a $13.00 price objective for the company. Finally, Stifel Nicolaus lowered their target price on shares of STAAR Surgical from $19.00 to $18.00 and set a “hold” rating on the stock in a research note on Wednesday, March 4th. One equities research analyst has rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $18.94.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.